HMPL-A580
/ Hutchmed
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 04, 2026
HUTCHMED (China) Limited…announces that it has initiated a Phase I/IIa clinical trial of HMPL-A580, HUTCHMED’s second novel Antibody-Targeted Therapy Conjugate (“ATTC”), in patients with unresectable, advanced or metastatic solid tumors in China and the US.
(GlobeNewswire)
- "The first patient received the first dose on March 4, 2026."
Trial status • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1